Insmed Inc (INSM)vsSenti Biosciences Inc (SNTI)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SNTI
Senti Biosciences Inc
$0.88
+2.30%
HEALTHCARE · Cap: $23.66M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 179315% more annual revenue ($606.42M vs $338,000). SNTI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SNTI
Avoid20
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SNTI
The strongest argument for SNTI centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SNTI
The primary concerns for SNTI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SNTI is a value play — different risk/reward profiles.
SNTI carries more volatility with a beta of 2.13 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SNTI generates stronger free cash flow (-9M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 20/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Senti Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Senti Biosciences Inc (SNTI) is a cutting-edge biotechnology company focused on revolutionizing synthetic biology to develop next-generation cell and gene therapies. Leveraging its proprietary GeneCircuit platform, Senti aims to create programmable therapies designed to address a variety of diseases, including cancer and genetic disorders, thus enhancing the precision of personalized medicine. With a strong development pipeline and strategic partnerships, Senti is well-positioned to lead advancements in engineered cell therapies, providing innovative solutions to address significant unmet medical needs in the biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?